NO COST TO HEALTHCARE PROFESSIONALS!

All programs are scheduled from 7:45 am – 4:30 pm (subject to change)
NO COST TO HEALTHCARE PROFESSIONALS

The Next Generation Migraine Therapies program is being offered to healthcare professionals at NO COST and will focus on providing only new and clinically relevant information via a series of didactic lectures, reviews of case studies, and interactive question-and-answer periods that will enhance basic understanding and improve prescribing techniques.

CME Statement: AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. AHS takes responsibility for the content, quality, and scientific integrity of this CME activity. AHS designates AMA PRA Category 1 credit(s)™ for this medical education activity, Next Generation Migraine Therapies, for a maximum of 7.5 credits. Each physician should claim credit commensurate with the extent of their participation in the activity.

For more information, call 856-423-0043 or email AHSHQ@talley.com. For complete program information and to register, visit www.AmericanHeadacheSociety.org

The Next Generation Migraine Therapies Program is Supported by an Education Grant from: Allergan, Amgen, Avanir, Depomed, Lilly, Supernus and Teva.
Saturday, April 6, 2019
Sheraton San Diego Hotel & Marina-Bay Tower
1590 Harbor Island Drive
San Diego, CA 92101

Saturday, May 18, 2019
Westin Galleria Dallas
13340 Dallas Parkway
Dallas, TX 75240

Saturday, June 8, 2019
Marriott Marquis New York
1535 Broadway
New York, NY 10036.
EDUCATIONAL OBJECTIVES

Upon completion of this program, participants will be better able to:

- Recognize the lack of awareness of the basic science and therapeutic potential of CGRP mAbs in the prevention of migraine.
- Identify mAbs, particularly CGRP and its receptor, provide effective prophylaxis of migraine.
- Address the need for greater understanding of how to apply new information about migraine pathophysiology to specific patients and potential treatments.
- Review data on the effectiveness and safety of mAbs in the treatment of migraine and learn how results in key subpopulations can help them predict which patients are likely to respond to treatment with CGRP mAbs.

PROGRAM

7:00 am – 7:45 am  Course Registration and Continental Breakfast

7:45 am – 8:00 am   Introduction, Program Overview and Pre-test

8:00 am – 9:00 am  State of the Art

Upon completion of this session, participants will be better able to:

- Review diagnostic criteria for migraine and the progression of episodic migraine to chronic migraine.
- Understand the epidemiology of migraine and the impact of migraine on daily life.
- Discuss migraine pathophysiology.

8:00 am – 8:20 am Episodic and Chronic Migraine: Diagnosis, Differential Diagnosis, Epidemiology, and Impact

(cont.)
### PROGRAM (cont.)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:20 am - 8:45 am</td>
<td>Pathophysiologic Foundations of New Therapeutics (applied pathophysiology)</td>
</tr>
<tr>
<td>8:45 am - 9:00 am</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>9:00 am - 9:50 am</td>
<td><strong>Next Generation Acute Treatment: Addressing Unmet Needs</strong></td>
</tr>
<tr>
<td>9:00 am - 9:10 am</td>
<td>Current Treatment &amp; Unmet Needs</td>
</tr>
<tr>
<td>9:10 am - 9:20 am</td>
<td>Unmet Needs: Speed, Consistency, Nausea, Poor Oral Absorption (Novel Approaches for Delivering Triptans, Ergots, NSAIDs and Other Acute Treatments)</td>
</tr>
<tr>
<td>9:20 am - 9:35 am</td>
<td>Cardiovascular Safety: Gepants (Small Molecule CGRP Receptor Blockers) and 5-HT1F (Lasmiditan)</td>
</tr>
<tr>
<td>9:35 am - 9:50 am</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>9:50 am - 10:10 am</td>
<td>Break</td>
</tr>
<tr>
<td>10:10 am - 12:00 pm</td>
<td><strong>Next Generation Preventive Treatment</strong></td>
</tr>
<tr>
<td>10:10 am - 10:25 am</td>
<td>Current Treatment and Unmet Needs</td>
</tr>
<tr>
<td>10:25 am - 10:40 am</td>
<td>Immunology, Antibodies and Monoclonal Antibodies</td>
</tr>
<tr>
<td>10:40 am - 11:10 am</td>
<td>Antibodies to CGRP and its Receptors</td>
</tr>
<tr>
<td>11:10 am - 11:20 am</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>11:20 am - 11:35 am</td>
<td>Neuromodulation</td>
</tr>
<tr>
<td>11:35 am - 11:50 am</td>
<td>Behavioral</td>
</tr>
<tr>
<td>11:50 am - 12:00 pm</td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>12:00 pm - 1:15 pm</td>
<td><strong>Working Lunch: Case Discussions</strong></td>
</tr>
<tr>
<td></td>
<td>All Faculty</td>
</tr>
</tbody>
</table>
Upon completion of this session, participants will be better able to:

- Identify patients with headache disorders who are candidates for peripheral nerve blocks, trigger point injections, and onabotulinumtoxinA injections.

- Gain an understanding of anatomical landmarks enabling safe and effective procedural headache therapy.

- Perform peripheral nerve blocks, trigger point injections, and onabotulinumtoxinA injections on models to optimize use in clinical practice.

This Workshop will highlight the role of nerve blocks, stimulators, and OnabotulinumtoxinA in the treatment of migraine and chronic migraine. The workshop will include a didactic session coupled with hands-on training.
1:15 pm - 2:00 pm  Current Devices and Devices to come with Q & A
2:00 pm - 2:45 pm  Behavioral Enhancements to Migraine Management with Q & A

2:45 pm - 3:00 pm  Break
(attendees switch rooms—workshops repeat)

3:00 pm – 3:45 pm  Current Devices and Devices to come with Q & A
3:45 pm - 4:30 pm  Behavioral Enhancements to Migraine Management with Q & A

Upon completion of this session, participants will be better able to:

• Assess patients who have contradictions to standard migraine treatments and may be candidates for alternative treatment strategies.

• Screen and identify patients who fail standard and preventative therapies and may be at risk of developing medication overuse or headache status deterioration.

• Utilize alternative neuromodulating treatments to reduce the severity, disability, and pain associated with migraine and other headache disorders.

This Workshop will review strategies for optimizing medical communication, enhancing patient adherence and self-efficacy, and creating tailored comprehensive treatment plans including empirically supported behavioral approaches.
GENERAL INFORMATION

TARGET AUDIENCE
This program is designed for neurologists, family practitioners, internal medicine, psychologists, and other health professionals who would like more information on the proper diagnosis and treatment of chronic migraine patients.

EDUCATION MISSION STATEMENT
The provision of quality CME is a primary mission of the American Headache Society® (AHS). AHS’s educational objectives are to continue to improve the knowledge, skills, and professional performance of physicians, psychologists, and other health professionals in the care of patients with head, neck, and orofacial pain by:
• Providing a forum for presentation of free scientific communication on research and clinical practice
• Providing educational symposia
• Improving education in medical schools and residency programs
• Identifying and developing new educational initiatives
• Supporting educational programs directed to people with head, neck, and orofacial pain
• Maintaining strict adherence to ACCME guidelines
• Developing educational activities and tools that are designed, and then evaluated, for their role in improving the learners’ competence, performance and the overall quality and safety of the care they give to individuals suffering from head, neck and orofacial pain.

CONTINUING MEDICAL EDUCATION CREDIT
CME Statement: AHS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. AHS takes responsibility for the content, quality, and scientific integrity of this CME activity. AHS designates AMA PRA Category 1 Credit(s)™ for this medical education activity, Comprehensive Migraine Education Program, for a maximum of 4.00 AMA PRA Category 1 Credit(s)™ for the morning program, 3.5 AMA PRA Category 1 Credit(s)™ for Workshop 1 and 3.5 AMA PRA Category 1 Credit(s)™ for Workshop 2.

Application for CME credit has been filed with the American Academy of Family Physicians (AAFP). Determination of credit is pending.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE STATEMENT
All contributors who can affect American Headache Society CME content (including but not limited to Leadership, Program Chairs, Program Committee Members, Moderators, Faculty, Speakers, Reviewers, Teachers, Authors, Medical Writers and Staff), in their respective roles, are required to disclose all relevant financial relationships with any commercial interest that could be viewed as a real or perceived conflict of interest. Contributors will also identify relevant financial relationships of their spouse, partner or immediate family.

This policy is in effect to maintain adherence with the conflict of interest guidelines set by the Accreditation Council for Continuing Medical Education (ACCME) and the American Headache Society Ethics Committee.

Prior to the program, attendees will be made aware of the presence or absence of relevant financial relationships for any contributors who may affect the development, management, presentation or evaluation of the CME activity. The presence or absence of relevant financial relationships for any contributor who affects content are listed in the Final Program, mobile app (where applicable), presented verbally and in slide form.

Individuals who refuse to disclose relevant financial relationships will be disqualified from being a contributor and cannot have control of, or responsibility for, the development, management presentation or evaluation of the CME activity.

SPECIAL NOTE FOR THE PHYSICALLY CHALLENGED
The American Headache Society® wishes to take steps to ensure that no individual with disability is excluded, denied services, segregated, or otherwise treated differently than other individuals because of the absence of auxiliary aids and services. If you need any auxiliary aids or services identified in the Americans with Disabilities Act, or any assistance in registering for this symposium, please contact AHSHQ at 856-423-0043, write AHS, 19 Mantua Road, Mt. Royal, NJ, 08061, or email AHSHQ@talley.com.

REGISTRATION
To register, at no cost to the healthcare professional, click here.

www.AmericanHeadacheSociety.org